Operation Ganbatte

A Strategic Sprint to Acquisition & Growth

The Ikigai Mission: Q4 2025 - A Return to Purpose

This is our high-leverage moment. We are pivoting from survival to strategic value creation through extreme focus, delivering a key IP asset that secures our future.

Q4

The Financial Reality: A Focused Plan

$85K

Required Funding Bridge

The strategic capital needed to cover six payrolls and operating expenses to fully execute the Polaris-R sprint.

Q4 Sprint Cost Coverage ($K)

Total Q4 operational cost ($309K) covered by four distinct financial levers.

The Ganbatte Sprint: Q4 Critical Timeline

1

Oct 21st: IMI Demo

The critical acquisition trigger. A successful demo proves our technical superiority and team value.

2

Nov 30th: Merck Proposal & API

Merck Beam Tracking proposal approved. Polaris-R analysis functions migrated. De-risks January revenue.

3

Dec 31st: Polaris-R v1 SHIPPED

Delivery of the final IP asset: a production-grade, high-speed simulation suite required for all Q1 2026 work.

The Value Proposition: Polaris-R

This transition ensures the Polaris legacy endures. Polaris-M remains your gold standard of scientific truth, capable of supporting your personal consulting work (e.g., Google). Polaris-R is the industrial-scale, super-conducting implementation that scales your science for AI/ML and global industry.

The Strategic Path to 2026

We are executing a dual-track strategy to maximize the chance of a positive outcome. The Ganbatte plan makes our asset valuable for both paths.

Track A: IMI Acquisition

(Highest ROI Objective)

➔

Position the team and IP for an asset purchase, securing jobs and liquidity for all equity holders.

OR

Track B: Fundraising

(Most Controllable Outcome)

➔

Leverage the completed Polaris-R asset to secure a high-valuation funding round for the new ODA platform.

The ROI & The Commitment

The Investment Thesis (Return)

  • The $85K bridge funds the final 20% of Polaris-R, which unlocks 100% of commercial value.
  • Primary Objective: The investment protects and enables the liquidation of your $1.8M total capital stack (Convertible Note + Deferred Equity Grants) through a successful exit
  • Confirms January Revenue: Polaris-R is a mandatory prerequisite to execute the confirmed Merck Beam Tracking contract (optimization/tolerancing).
  • Downside Protection: The bridge investment pays for itself through the confirmed Merck revenue, even if Track A (Acquisition) fails.

Illuminating the Total Team Sacrifice

  • Chairman's Capital Burden: Since Feb 2025, the Chairman has supported the stability of the company with nearly $400K in capital investment, bearing the primary financial risk.
  • Team's Human Capital: Our team's sacrifice is measured in a year of endured uncertainty, including a furlough, and highly skilled engineers accepting below-market compensation. Their continued presence is the high-value asset we sell.
  • The Q4 Commitment: The team is committed to maximum productivity to complete Polaris-R and is converting their equity risk into liquidity through this sprint.
  • President's Contribution: The $19K salary reduction directly protects the company's Q4 cash flow and streamlines the balance sheet for acquisition.

The Q1 2026 Payoff

🤝

Acquisition & Stability

Secures liquidity for the Chairman's nest egg, enables a potential IMI Science Advisor role, and provides jobs for the team.

💰

Confirmed Revenue

The execution of the Merck Beam Tracking project starts, securing $60K - $250K in Q1 revenue.

📈

Enhanced Valuation

The completed Polaris-R asset makes the IP a far more seductive purchase for investors or acquirers.